Financials
| 9M and Q3 2024 Results | Nov. 12, 2024 |
| Half-year Report | Jul. 25, 2024 |
| 1st Quarter Results | Apr. 25, 2024 |
| 9M and Q3 2023 results | Nov. 09, 2023 |
| Half-year Report | Jul. 28, 2023 |
| 1st Quarter Results | Apr. 27, 2023 |
| AZ 2022 Annual Report XBRL | Feb. 21, 2023 |
Proxies
| Special Business Approved at AGM | Apr. 12, 2024 |
| Proxy Form for 2024 AGM | Mar. 07, 2024 |
| Notice of AGM | Mar. 07, 2024 |
| Notice of AGM | Mar. 07, 2024 |
| Special Business Approved at AGM | Apr. 27, 2023 |
| Result of AGM | Apr. 27, 2023 |
| Notice of AGM | Mar. 22, 2023 |
Ownership Update
| Director/PDMR Shareholding | Nov. 20, 2024 |
| Director/PDMR Shareholding | Nov. 15, 2024 |
| Director/PDMR Shareholding | Nov. 15, 2024 |
| Director/PDMR Shareholding | Nov. 13, 2024 |
| Director/PDMR Shareholding | Jun. 12, 2024 |
| Director/PDMR Shareholding | May. 15, 2024 |
| Director/PDMR Shareholding | Mar. 12, 2024 |
Announcements
| Imfinzi approved in US for limited-stage SCLC | Dec. 05, 2024 |
| Block listing Interim Review | Dec. 02, 2024 |
| Total Voting Rights | Dec. 02, 2024 |
| Truqap improved rPFS in advanced prostate cancer | Nov. 25, 2024 |
| Tagrisso recommended for EU approval - LAURA | Nov. 18, 2024 |
| AstraZeneca invests $3.5 billion in US | Nov. 12, 2024 |
| KOMET Phase III trial met primary endpoint | Nov. 12, 2024 |
Prospectuses
| AstraZeneca prices a €1.4bn bond offering | Jul. 30, 2024 |
| AstraZeneca prices a $5bn bond offering | Feb. 22, 2024 |
| AstraZeneca prices a $2.25bn bond offering | Mar. 01, 2023 |
| AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | Jun. 15, 2022 |
| AstraZeneca prices a EUR800m bond offering | May. 27, 2021 |
| AstraZeneca prices a $7bn bond offering | May. 26, 2021 |
| AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | May. 24, 2021 |